Activation of NK cells is regulated by opposing receptors that trigger inhibitory and stimulatory pathways 1 . The inhibitory signaling pathways are well characterized. On binding to major histocompatibility complex (MHC) class I molecules, the phosphorylated immunoreceptor tyrosine-based inhibitory motifs (ITIMs) present in the intracytoplasmic domain of inhibitory receptors recruit Src homology domain 2-bearing tyrosine phosphatase 1 (SHP-1). This phosphatase dephosphorylates crucial substrates of protein tyrosine kinases (PTKs), thereby blocking the activation of NK cells 2 . In contrast, the stimulatory pathways are diverse and can be initiated by several receptors binding to antibody-coated cells, adhesion molecules, cytokines, and cellular ligands expressed on stressed, infected or transformed cells, and by pathogen-associated molecules 3 .
Activation of NK cells is regulated by opposing receptors that trigger inhibitory and stimulatory pathways 1 . The inhibitory signaling pathways are well characterized. On binding to major histocompatibility complex (MHC) class I molecules, the phosphorylated immunoreceptor tyrosine-based inhibitory motifs (ITIMs) present in the intracytoplasmic domain of inhibitory receptors recruit Src homology domain 2-bearing tyrosine phosphatase 1 (SHP-1). This phosphatase dephosphorylates crucial substrates of protein tyrosine kinases (PTKs), thereby blocking the activation of NK cells 2 . In contrast, the stimulatory pathways are diverse and can be initiated by several receptors binding to antibody-coated cells, adhesion molecules, cytokines, and cellular ligands expressed on stressed, infected or transformed cells, and by pathogen-associated molecules 3 .
Receptors such as FcγRIII and the CD94-NKG2C complex in human and mouse, the killer cell immunoglobulin-like receptors and certain natural cytotoxicity receptors in humans, and Ly49H and Ly49D in mice initiate signaling cascades that resemble those triggered by antigen receptors on B and T lymphocytes 4 . These receptors associate with immunoreceptor tyrosine-based activation motif (ITAM)-bearing adaptor molecules such as CD3ζ, FcγRIII and DAP12, which are probably phosphorylated by membrane-associated Src-family PTKs when activated. Phosphorylation of the tyrosines in ITAMs generates docking sites for the intracellular Syk family PTKs Syk and ZAP70.
The recruited Syk and ZAP70 are activated in turn and can phosphorylate many signaling molecules that initiate NK cellular programs for granule release and/or gene transcription. This eventually results in target cell lysis and the production of cytokines and chemokines. Whereas B and T cells require ITAM-mediated signals for their development and activation, NK cells are unique in that they are the only lymphocytes to develop, differentiate and fully reject MHC class I-deficient tumor cells in the absence of both Syk and ZAP70 (ref. 5) .
NKG2D is an activating receptor that is expressed on human and mouse NK cells, some T cells 6 and activated mouse macrophages 7 . NKG2D recognizes UL16-binding protein 1 (ULBP1), ULBP2, ULBP3 and MHC class I chain-related molecules (MICA and MICB) in humans 6, 8 , and minor histocompatibility antigen 60 (H-60), retinoid acid early inducible transcript (Rae-1) and murine ULBPlike transcript 1 in mice 7, 9, 10 . Most of these ligands are expressed either by normal mouse tissues early in ontogeny or by stressed, infected and tumor cells in adult life 11 . Expression of these ligands renders some tumor cell lines susceptible to NK cell killing, including those that have normal MHC class I expression 12, 13 . Thus, NKG2D can overcome the protection provided by MHC class I expression and is therefore an excellent sentinel system that activates diverse immune cells on recognition of infected or transformed cells 11 .
NKG2D homodimers associate with the adaptor molecule DAP10, which does not have an ITAM but contains the consensus p85 PI3K-binding motif Tyr-Ile-Asn-Met (YINM) 14 . Because this motif is also found in CD28 and inducible costimulator (ICOS), NKG2D-DAP10 may mediate costimulation rather than full activation. Indeed, NKG2D can substitute for CD28-mediated costimulation but cannot activate T cells in the absence of a T cell antigen receptor (TCR)-induced signal 15 . In activated mouse NK cells, NKG2D is sufficient to trigger cytokine production 15 , whereas in human NK cells NKG2D requires additional ITAM-mediated signals to initiate cytokine production 16 .
These differences may be due to the fact that mouse NK cells express an RNA splice variant of NKG2D (designated 'NKG2D-short') that associates with both DAP12 and DAP10 to activate Syk-and ZAP70-dependent signaling cascades 17, 18 . In contrast, the NKG2D isoform designated 'NKG2D-long' associates with DAP10 but not DAP12 (refs. 17,18) . According to the current model, alternative associations with these two distinct adaptors determine the signaling outcome. NKG2D-DAP10 mediates costimulation, whereas NKG2D-DAP12 mediates activation 19 .
Natural cytotoxicity is at least partially dependent on NKG2D 15 , but it does not require Syk and ZAP70 (ref. 5) . In light of these observations, we have questioned the model in which activation of NK cells by NKG2D is strictly dependent on the DAP12-Syk-ZAP70 pathway [17] [18] [19] . Here we report our results from studies of the effector functions of NK cells deficient in either DAP12 or the two Syk family PTKs Syk and ZAP70.
RESULTS

Hematopoietic mouse chimeras and NKG2D expression
NK cells can be activated by many receptors that transduce signals by diverse strategies. In mice, NKG2D is unique in that it can initiate the PI3K and the Syk-ZAP70 PTK pathways by associating with the adaptors DAP10 and DAP12, respectively. We are interested in whether these pathways are equivalent in their capacity to trigger NK cell functions. For example, do they differentially mediate activation and costimulation, or do they differentially regulate NK cell effector functions? To study the role of the DAP12-Syk-ZAP70 pathway in NKG2D signaling in mouse NK cells, we analyzed NKG2D functions in mice deficient for both Syk and ZAP70 or DAP12.
To overcome the embryonic lethality of the null mutation in the Syk gene 20 , we prepared hematopoietic chimeras by reconstituting Rag2 −/− Il2rg −/− alymphoid mice with fetal liver cells from Syk −/− Zap70 −/− embryos. Because these chimeras develop NK cells but no B or T cells 5 , we prepared control chimeras in which the alymphoid mice were reconstituted with fetal liver cells from age-matched Rag1 −/− embryos. These are the best-matched controls, as they fail to develop B and T cells but develop NK cells normally. We refer to the different groups of mice as
The numbers of splenic NK cells were comparable between the two groups of chimeras and were undetectable in nonreconstituted alymphoid mice (ref. 5 and data not shown). Expression of NKG2D was detected on nearly all NK cells in the spleen and peritoneal cavity and on interleukin-2 (IL-2)-activated NK cells (Fig. 1a,b) . The expression of NKG2D was slightly higher on splenic NK cells from Syk −/− Zap70 −/− 566 VOLUME 4 NUMBER 6 JUNE 2003 NATURE IMMUNOLOGY chimeras (mean fluorescence intensity 79 ± 6) than on NK cells from controls (58 ± 6, n = 4, P = 0.01), whereas no significant difference in NKG2D expression between the two groups was observed on NK cells activated by IL-2 (55 ± 13 in Syk −/− Zap70 −/− and 56 ± 17 in controls, n = 3). 12, 13 . IL-2-activated Tyrobp −/− and Syk −/− Zap70 −/− NK cells could readily lyse both types of Rae-1γ-transfected cell, overcoming the inhibition imposed by MHC class I molecules expressed by the parental RMA cells (Fig. 2a,b) . In accordance with published data 5 , IL-2-activated Syk −/− Zap70 −/− NK cells also efficiently killed MHC class I-deficient RMA-S tumor cells and NK cell-sensitive YAC-1 tumor cells, even though the natural killing of YAC-1 targets has been shown to be largely dependent on NKG2D 15 .
NKG2D-initiated cytotoxicity in activated NK cells
It is possible that IL-2 activation nonspecifically augments NK cell activity, by overcoming possible signaling defects in mutant NK cells. Ly49D and Ly49H are two receptors that activate cytotoxicity through the DAP12-Syk-ZAP70 pathway, and Ly49D enhances the killing of Chinese hamster ovary (CHO) tumor cells 21 . In a control experiment, IL-2 did not rescue the defective killing of CHO targets by Ly49D-positive purified Syk −/− Zap70 −/− NK cells (57% specific lysis for control and 17% specific lysis for Syk −/− Zap70 −/− NK cells at a ratio of 9:1; data not shown). Similarly, IL-2 did not rescue the defective Ly49H-mediated killing of cytomegalovirus m157-bearing target cells by Tyrobp −/− NK cells 22 .
Polyinosinic-polycytidylic acid (poly(I-C)) simulates doublestranded RNA and induces the production of interferon-α (IFN-α) and IFN-β, which are potent activators of NK cell cytotoxicity, proliferation and migration 23 . Poly(I-C) also induces the expression of NKG2D-short 17, 18 . Consistent with our data on IL-2-activated NK cells, splenic NK cells from Syk −/− Zap70 −/− chimeras treated with poly(I-C) could kill RMA-Rae-1γ cells in vitro (Fig. 2c) . This NKG2D-induced killing was specific, because a monoclonal antibody to NKG2D (anti-NKG2D) inhibited most killing in both control and Syk −/− Zap70 −/− NK cells (Fig. 2d) .
We conclude that the DAP10-PI3K pathway is sufficient, whereas the DAP12-Syk-ZAP70 pathway is dispensable, for NKG2D-mediated cytotoxicity in activated mouse NK cells, at least against the tumors evaluated in these studies.
Inhibition of PI3K blocks NKG2D-initiated cytotoxicity
We considered that IL-2-activated Syk −/− Zap70 −/− NK cells might use the DAP10-PI3K pathway for NKG2D activation. To test this possibility, we measured the capacity of Syk −/− Zap70 −/− NK cells to kill RMA-Rae-1γ cells in vitro in the presence of increasing amounts of the PI3K-specific inhibitor LY294002. The lysis of RMA-Rae-1γ cells in the presence of a dimethylsulfoxide (DMSO) vehicle was considered as the basal level. The PI3K inhibitor blocked the lysis of RMA-Rae-1γ cells in a dose-dependent manner, reaching 50-60% inhibition in both Syk −/− Zap70 −/− and control NK cells (Fig. 3) . No significant difference was observed between mutant and control NK cells. On the basis of these results, we conclude that the PI3K has a key role in the activation of NKG2D function, regardless of the availability of the NKG2D-DAP12-Syk-ZAP70 pathway.
Enhanced cytotoxicity independent of DAP12 and Syk-ZAP70
To test directly the capacity of NKG2D to enhance cytotoxicity in the absence of DAP12 or Syk-ZAP70, we measured the redirected (Fig. 4a,b) . Taken together, these results are consistent with the hypothesis that NKG2D can signal in the absence of the DAP12-Syk-ZAP70 pathway, and that DAP10-stimulated PI3K may be sufficient to trigger NKG2D-mediated cytotoxicity in activated NK cells.
In vivo rejection of tumors expressing NKG2D ligands
When injected into mice, MHC class I-negative RMA-S cells and MHC class I-positive RMA-Rae-1γ cells are eliminated by NK cells, but MHC class I-positive RMA cells are much less susceptible to elimination 12, 13, 24 . We therefore evaluated the capacity of NK cells to discriminate between different target cells in vivo. RMA-S cells and RMA-Rae-1γ cells were labeled with the vital dye carboxyfluorescein diacetate succinimidyl diester (CFSE). Equivalent numbers of RMA-S and RMA-Rae-1γ cells (2 × 10 5 ) were injected into the peritoneal cavity of different groups of mice, together with the same numbers of mock-transfected RMA cells. An aliquot of the cell mixture was kept in culture. After 48 h, the cultured tumor cells were labeled with a monoclonal antibody to MHC class I and the numbers and relative proportions of the different types of cell were calculated.
The three tumor cell lines could be readily discriminated by the expression of MHC class I molecules and CFSE fluorescence (Fig. 5a) . RMA-S cells were reproducibly less represented, owing to a division rate only one-half to one-third as fast as for RMA and RMA-Rae-1γ cells (data not shown). Mice that received the injection of tumor cells were killed after 48 h. Consistent with the in vitro data, RMA-S cells were underrepresented in the peritoneal exudate cells (PECs) of alymphoid mice (Fig. 5a) ; however, the proportions of RMA, RMA-S and RMA-Rae-1γ cells in the PEC of alymphoid mice were comparable to those of the cells kept in culture (Fig. 5b) . This suggests that the cells in the peritoneal cavity of alymphoid mice do not have an NKlike activity, regardless of the expression of either MHC class I molecules or NKG2D ligands on the tumor cells.
Steady-state numbers of NK cells in the peritoneal cavity were similar in both control and Syk −/− Zap70 −/− chimeras, with 26 ± 6 × 10 3 NK cells in control chimeras (n = 7) and 22 ± 9 × 10 3 NK cells in Syk − /− Zap70 −/− chimeras (n = 6). The number of NK cells increased after the injection of tumor cells, possibly owing to recruitment 25 , reaching 88 ± 39 × 10 3 in control chimeras (n = 4) and 101 ± 10 × 10 3 in Syk −/− Zap70 −/− chimeras (n = 4). NK cells were undetectable in alymphoid mice before and after the injection of tumor cells (data not shown). The expression of NKG2D on mutant NK cells was comparable to that on control NK cells in the peritoneal cavity (Fig. 1a) .
We recovered 5.9 ± 4.2 × 10 3 RMA-Rae-1γ cells in control chimeras, 45 ± 17 × 10 3 in Syk −/− Zap70 −/− chimeras, and 285 ± 116 × 10 3 in alymphoid mice (Fig. 5a,b) . That is, Syk −/− Zap70 −/− chimeras rejected less RMA-Rae-1γ tumor cells than control chimeras (P = 0.05), but more than alymphoid mice (P = 0.04). This result suggests that NK cell activity, albeit lower than observed in wild-type mice, is triggered by NKG2D in the absence of Syk and ZAP70 PTKs (Fig. 5b) . Consistent with the in vitro data (Fig. 2c) with poly(I-C) before the tumor challenge resulted in the enhanced elimination of RMA-Rae-1γ cells (data not shown).
Despite a partial defect in eliminating RMA-Rae-1γ cells in vivo, Syk − /− Zap70 −/− chimeras were comparable to control wild-type chimeras in eliminating RMA-S cells. Only background numbers of RMA-S cells could be recovered in both groups of chimeras (1 ± 0.8 × 10 3 in Syk −/− Zap70 −/− and 0.1 ± 0.1 × 10 3 in control chimeras; not significant). In contrast, at least 100 times more RMA-S cells were present in alymphoid mice (93 ± 43 × 10 3 , P < 0.05 versus both Syk −/− Zap70 −/− and control chimeras). Thus, a Syk-ZAP70-independent and NKG2D-independent pathway of natural cytotoxicity is effective in eliminating RMA-S cells in vivo, as shown previously 5 , whereas the Syk-ZAP70 pathway is necessary for the full activity of NK cells to eliminate RMA-Rae-1γ cells in vivo.
The number of RMA cells recovered in NK-competent mice (102 ± 20 × 10 3 in Syk −/− Zap70 −/− and 65 ± 19 × 10 3 in control chimeras; not significant) was reproducibly lower than that recovered in alymphoid mice (370 ± 82 × 10 3 ). Thus, low NK cell activity against the parent RMA cells could account for this significant difference (P = 0.005 for Syk −/− Zap70 −/− and P = 0.002 for control chimeras versus alymphoid mice).
These results show that Syk −/− Zap70 −/− NK cells can efficiently eliminate RMA-S cells, but their elimination of MHC class I-positive RMA-Rae-1γ cells is partially impaired. Even so, Syk −/− Zap70 −/− NK cells show a consistent and significant activity against tumor cells that express NKG2D ligands.
NKG2D-initiated cytotoxicity in resting NK cells
Freshly isolated, resting Syk −/− Zap70 −/− NK cells could efficiently kill YAC-1 cells 5 (Fig. 6) , which express high levels of NKG2D ligands 7, 9 . This activity was inhibited by anti-NKG2D, suggesting that NKG2D-mediated killing of this target is independent of the DAP12-Syk-ZAP70 pathway (Fig. 6) . However, unlike activated NK cells but mirroring the in vivo situation, Syk −/− Zap70 −/− NK cells were less efficient than were wild-type NK cells in killing Rae-1γ-transfected RMA (P < 0.0001) and Ba/F3 cells (P < 0.0001) (Fig. 6) .
It has been suggested that NKG2D-initiated killing is dependent on DAP12 even when NK cells are activated with IL-2 (ref. 18). Our timecourse study showed that significant differences between control and mutant cells were still detectable by day 3 of culture in the presence of IL-2 (P < 0.05; Fig. 7) . By day 6, however, Syk −/− Zap70 −/− NK cells were fully capable of killing RMA target cells expressing NKG2D ligands (P > 0.05; Fig. 7 ). In addition, the ability of Syk −/− Zap70 −/− NK cells to kill YAC-1 target cells efficiently was not affected by IL-2 stimulation at any time in the culture period. Thus, the signaling requirements for NKG2D-initiated cytotoxicity may vary according to the activation state of NK cells and to the target cells used. At the least, a functional DAP12-associated NKG2D-short splicing variant is not absolutely required for NKG2D-initiated cytotoxicity in activated NK cells.
NKG2D-initiated cytokine production
In addition to cytotoxicity, an important NK cell effector function is cytokine production. Anti-NKG2D stimulates IFN-γ production in mouse but not human NK cells 16, 26 , but what is the cause of this species difference? It is possible that NKG2D acts as an activating receptor in mouse NK cells but functions only as a coreceptor in human NK cells. Alternatively, the NKG2D-short isoform that is able to pair with DAP12 may exist in activated mouse NK cells but not in human NK cells. 
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Both Tyrobp −/− and Syk −/− Zap70 −/− IL-2-activated NK cells failed to produce IFN-γ when stimulated with plate-bound anti-NKG2D, but they produced IFN-γ in response to IL-12 or control (anti-NK1.1 or anti-CD11b) monoclonal antibodies (Fig. 8a,b) . These results show that NKG2D-initiated IFN-γ production is strictly dependent on the DAP12-Syk-ZAP70 pathway.
DISCUSSION
Activation of NK cells is the result of a net excess of positive over negative signals. Although the molecular mechanisms of negative regulation have largely been identified 2 , we are only beginning to understand the receptors and the signaling molecules that drive NK cell activation 3, 4 . Some activating NK cell receptors use ITAM-bearing adaptor molecules and Syk family PTKs, whereas others do not associate with such adaptors and thus do not depend on these PTKs 5 . The attractiveness of NKG2D as a sentinel system of the innate immune system stems from three features. First, NKG2D binds to diverse ligands expressed by 'stressed or altered self ' , thereby complementing the missing self-recognition strategy of NK cells 27 . Second, in general these ligands are not expressed on healthy cells and are induced only on insult such as infection or transformation 11 . Third, NKG2D ligation can drive NK cell activation despite the inhibitory influence of MHC class I molecules expressed on target cells 12, 13 . An important issue is whether NKG2D alone can trigger NK cell activation (and, if so, how) or whether it simply augments NK cell activation above a critical threshold.
NKG2D has been thought to function like CD28 and ICOS, which provide PI3K-dependent costimulation of T cells and indeed can substitute for CD28 (ref. 28) . The concept of costimulation may not be strictly applicable to NK cell physiology, however, because NK cells do not express a central activating receptor like the antigen receptors in T and B cells. For example, costimulatory molecules such as CD28, CD40 and ICOS cannot activate T cells, but in some circumstances they can each independently trigger cytotoxicity in NK cells [29] [30] [31] .
We have shown here that NKG2D-DAP10 is sufficient to trigger cytotoxicity but not cytokine production in activated mouse NK cells. In the context of cell-mediated cytotoxicity, it is likely that NKG2D is stimulated concomitantly with other receptors. Our results showing the ability of NK cells lacking either DAP12 or Syk family PTKs to kill different types of NKG2D-bearing tumor cell indicate that pathways other than ITAM-based receptor systems may be important in activated mouse NK cells.
Why do Syk −/− Zap70 −/− mice have a reduced capacity to eliminate tumor cells expressing NKG2D ligands? It is unlikely that the defective cytokine production causes this phenotype, because elimination of tumor cells expressing NKG2D ligands is dependent on the secretion of perforin but not IFN-γ 32 . In Syk −/− Zap70 −/− or Tyrobp −/− NK cells, NKG2D can initiate only the DAP10-induced PI3K pathway. In wild-type NK cells, however, several receptors may trigger other signaling cascades, including receptors other than NKG2D that are linked to the DAP12-Syk-ZAP70 pathway. The activating signals responsible for initiating cytolytic activity are thought to converge on downstream signaling molecules such as Vav1. In accordance with this model, Vav1 −/− NK cells have severely impaired NKG2D function (S.Z. and F.C., unpublished data). In the absence of Syk and ZAP70 PTKs, the overall activating input will be decreased, making it more difficult to overcome the negative regulation, yet permitting efficient killing of MHC class I-deficient tumors. In activated NK cells, the weaker negative regulation imposed by MHC class I inhibitory receptors 27 is overcome by recruitment of DAP10-PI3K or DAP12-Syk-ZAP70 by NKG2D, and by the positive input from cytokines such as IL-15, IL-2 and IL-12, or IFN-α and IFN-β. Thus, in activated mouse NK cells, NKG2D can trigger cytotoxicity through a dual 'on-switch' involving DAP10 or DAP12.
The dual on-switch model for the alternative association of NKG2D with DAP12 and DAP10 is consistent with studies of mice lacking DAP10 (ref. 17) . Activated NK cells of DAP10-deficient mice showed a decrease in cytotoxicity against targets expressing NKG2D ligands 17 , similar to what we observed when the DAP10-associated PI3K pathway was specifically blocked by a pharmacological inhibitor. Thus, in the absence of DAP12 (refs. 18,22) or its associated Syk and ZAP70 PTKs (this work), or DAP10 (ref. 17) or its associated PI3K (this work), NKG2D function is retained, albeit reduced. If NKG2D is a dual on-switch receptor, mice deficient for both DAP12 and DAP10 should show completely defective NKG2D function.
Analysis of the role of NKG2D in human 16 and mouse 15 NK cells has generated conflicting data. Human NK cells stimulated with anti-NKG2D show enhanced killing of FcR-expressing target cells 16 , whereas cytokine production can be induced only with the concomitant stimulation of an additional ITAM-bearing activating receptor 16 . This suggests that NKG2D works mainly as a costimulatory receptor for cytokine production in human NK cells but is competent to activate cell-mediated cytotoxicity. In contrast, stimulation of activated mouse NK cells with anti-NKG2D results both in enhanced cytolysis of FcR-expressing target cells and in cytokine production 15 . These results have been interpreted to mean that NKG2D in activated mouse NK cells acts as an independent trigger of NK cells. Yet mouse NK cells, when activated with IL-2 or poly(I-C), express a RNA splice variant of NKG2D that can associate with both DAP10 and DAP12 (refs. 17,18) . A lack of direct NKG2D-induced cytokine production in human NK cells may be explained by the lack of an human NKG2D isoform that can associate with human DAP12. Although our results support the concept that DAP12 is required for NKG2D-induced cytokine production by mouse NK cells, they indicate that ITAMbased signaling is not required for NKG2D-dependent cytotoxicity in mouse or human NK cells 26 . Signaling divergence that segregates cytolytic activity and cytokine production has been documented previously for other NK cell receptors, such as 2B4 (ref. 33) , and for signaling proteins 34 .
Activated CD8 + T cells express both NKG2D isoforms and DAP10 but not DAP12, recapitulating the situation of activated Tyrobp −/− and Syk −/− Zap70 −/− NK cells, in which only the DAP10-PI3K pathway is available. So why does NKG2D fail to trigger responses in activated CD8 + T cells, where it only functions as a costimulator? The explanation may lie in the intrinsic properties of NK and T cell biology. Whereas NK cell activation is the result of concurrent signals from several receptors that reach a given threshold sufficient to overcome suppression by inhibitory receptors for MHC class I molecules, T cell activation is dominated by stimulation through the TCR. In addition, activation may depend on the response being measured. IFN-γ production and proliferation are not induced by NKG2D in CD8 + T cells 15, 18 . In some circumstances, however, for example when CD8 + T cells are exposed to high doses of IL-2 in culture, they acquire 'lymphokine-activated killer' activity and behave like NK cells, killing target cells. We suspect that in these situations, NKG2D-DAP10 on these T cells may be responsible for this 'promiscuous' killing. Whether this occurs in vivo is uncertain.
A model has been proposed in which the promiscuous association of mouse NKG2D with the DAP10 and DAP12 adaptors determines costimulation or activation 17, 18 . Although elegant, this model fails to explain how cytotoxicity can be triggered by NKG2D in Syk −/− Zap70 −/− or Tyrobp −/− activated mouse NK cells. An alternative explanation for the promiscuous association of one receptor to distinct adaptors and pathways is the availability of a dual on-switch system that can trigger NK cell cytotoxicity in many situations, adding to the redundancy of signaling pathways that can trigger cytotoxicity in NK cells 3 . For example, in an inflammatory microenvironment, the main stimulus for IFN-γ production is likely to be IL-12. Therefore, NKG2D may not be a crucial trigger for cytokine production, but it may be essential for triggering cytotoxicity against 'stressed' cells. DAP12 is an adaptor shared by several different receptors, and thus its availability in the activated cell may be limiting. By being able to activate an alternative DAP12-independent pathway, NKG2D provides NK cells with more choices 27 in addition to the flexibility it confers through its capacity to interact with many ligands. Thus, this versatile association with multiple signaling pathways enables the threshold for activating cytotoxicity to be achieved in different situations, even when one signaling pathway is not available.
METHODS
Mutant mice and hematopoietic mouse chimeras. Fetal liver chimeras were generated as described previously. In brief, Rag2 −/− Il2rg −/− (H-2 b ) alymphoid mice 35 aged 4-6 weeks were irradiated with 300 rad and then received 5 × 10 6 fetal liver cells. Mice that were heterozygous for the Syk tm1Tyb mutation 20 and homozygous for the Zap70 mutation 36 , which had been backcrossed for six and two generations, respectively, onto the B10.D2 background (H-2 d ), were crossed to generate day 14.5-16.5 embryos. In parallel, we crossed 129 mice homozygous for the Rag1 mutation 37 , which had been backcrossed for ten generations onto the C57BL/10 background and for two subsequent generations onto the B10.D2 background (H-2 d ), to generate age-matched embryos. DAP12-deficient (Tyrobp −/− ) mice have been described 38 . All protocols for animal experiments were reviewed by the Central Animal Facilities of the Institut Pasteur and were done in accordance with guidelines approved by the French Ministry of Agriculture.
Radioactivity-free assay for tumor rejection in vivo. The tumor cells lines RMA (mock transfected), RMA-S and RMA-Rae-1γ (RMA transfected with the NKG2D ligand Rae-1γ) were cultured in RPMI-1640 medium (Gibco-BRL) supplemented with 10 −5 M β-mercaptoethanol (β-ME, Sigma), 10% fetal calf serum (FCS), 100 µg/ml of streptomycin and 100 U/ml of penicillin (all from Gibco-BRL). At the exponential proliferation stage, the RMA-S and RMA-Rae-1γ cells were labeled with 5 µM CFSE. In brief, we suspended the cells (10 7 per ml) in PBS plus 2% FCS and labeled them at 37 °C for 10 min. After one wash in RPMI-1640 medium plus 10% FCS, the cells were resuspended in an appropriate volume of PBS plus 2% FCS. The same number of RMA cells (2 × 10 5 ) was labeled with the vital dye PKH26 (5 µM, Sigma). RMA cells were resuspended (2 × 10 7 per ml) in the appropriate labeling diluent (Sigma) and mixed with a 2× solution of PKH26 (10 µM) for 5 min at 22 °C. Such labeling was done to discriminate the MHC class I (H-2 b )-positive RMA cells from the host-derived cells (H-2 b ) resident in the peritoneal cavity of the chimeras. The cells were then washed twice in RPMI-1640 plus 10% FCS and were resuspended in appropriate volume of PBS plus 2% FCS. After labeling, the cells were mixed and injected in the peritoneal cavity (2 × 10 5 cells of each type, a total of 6 × 10 5 cells in a volume of 600 µl per mouse). We kept an aliquot of the mixed cells in culture. After 48 h, the mice were killed and the PECs were recovered.
Flow cytometry. We suspended the PEC cells in PBS plus 2% FCS. For immunofluorescence analysis, 10 6 cells were stained with a monoclonal antibody to NK1.1 conjugated to allophycocyanin and a monoclonal antibody to H-2K b conjugated to biotin (both from PharMingen). The biotin-conjugated antibody was detected with streptavidin-PerCP (PharMingen). In parallel, mixed cells cultured in vitro were stained. Electronic gates were set to acquire 1 × 10 4 tumor cells positive for CFSE or PKH26. A first gate was set on large cells on the basis of their forward and side light-scattering profile. We then set two gates on CFSE-and PKH26-positive cells. Final analysis was done on the cells included in the two latter gates. For splenocytes, we prepared single-cell suspensions as described 35 . Cells were stained with anti-NK1.1 conjugated to phycoerythrin (PE) or allophycocyanin, anti-CD122 (IL-2Rβ) conjugated to fluorescein isothiocyanate (FITC), and a rat anti-mouse NKG2D (clone CX5 or CX7) generated as described 39 and detected by a PE-conjugated donkey anti-rat IgG (Jackson Laboratories). We did the analysis on a FACSCalibur flow cytometer with CellQuest software (Becton Dickinson).
NK cell cytotoxicity in vitro.
We used a 4-h 51 Cr release assay to measure NK activity in vitro as described 35 . Target cells (YAC-1, RMA, RMA-S, RMA-Rae-1γ, Ba/F3, Ba/F3-Rae-1γ, CHO, Daudi and 712.221-CD32 transfectants) were labeled with 100 µCi of 51 Cr (ICN Pharmaceuticals). Red cell-depleted splenocytes were used fresh, after 30 min of plate adherence to remove most granulocytes and monocytes, or were cultured in RPMI-1640 supplemented with 10% FCS, 10 −5 M β-ME, 100 µg/ml of streptomycin, 100 U/ml of penicillin and 1,000 U/ml of human IL-2 (R&D Systems). For fresh NK cells from Syk −/− Zap70 −/− and control chimeric mice, we adjusted the number of effector cells by the actual number of NK1.1 + CD122 + NK cells.
Splenic mononuclear cells from C57BL/6 and Tyrobp −/− mice aged 6-8 weeks were prepared by passing spleens through a steel mesh, and erythrocytes were lysed in an ammonium chloride solution (Sigma). We enriched NK cells by T cell and B cell depletion. In brief, spleen cells were incubated with monoclonal antibodies to CD4 (clone GK1.5) and CD8 (clone 53-6.7) and mixed with magnetic microbeads coated with goat anti-mouse IgG and goat anti-rat IgG (Advanced Magnetic). CD4-, CD8-and membrane immunoglobulin (mIg)-positive cells were removed by magnetic cell sorting. The CD4-, CD8-and mIg-depleted splenocytes were stained with a PE-conjugated pan monoclonal antibody to NK cells (DX5, PharMingen) and incubated with magnetic microbeads coated with antibodies to PE (Miltenyi Biotec). DX5-positive cells were then isolated by magnetic cell sorting with a MACS (Miltenyi Biotec). The purity of the DX5-positive cells was more than 95%, as determined by flow cytometric analysis. We cultured the purified NK cells in RPMI-1640 supplemented with 10% FCS and 5 × 10 −5 M β-ME in the presence of 4,000 U/ml of human recombinant IL-2.
For antibody-blocking experiments, fresh NK cells were incubated with anti-NKG2D (CX7) or a control rat anti-mouse I-A b IgG anti-I-A for 30 min at 22 °C before the 4-h 51 Cr release assay was done with target cells that do not express FcR (YAC-1 or RMA-Rae-1γ). To measure redirected antibody-dependent cellular cytotoxicity (R-ADCC), we incubated IL-2-activated NK cells with anti-NKG2D (CX5) or an isotype-matched control rat anti-mouse I-A b ) for 15 min at 37 °C before the 4-h 51 Cr release assay was done with target cells that express FcR (human Daudi B-cell lymphoma or human 712.221-CD32 transfectants). PI3K inhibition experiments were done as described 5 .
Cytokine production. Tissue culture plates were coated with 1 mg ml -1 of N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP; Sigma) for 10 min at 22 °C (to enhance antibody binding to plates), washed with PBS, incubated with antibodies diluted in 0.1 M sodium bicarbonate buffer (pH 9.0) for 16 h at 4 °C and then washed with PBS. To block Fc receptor-dependent activation, we pretreated IL-2-activated NK cells with 10 µg/ml of soluble 2.4G2 monoclonal antibody to CD16/32 for 30 min. NK cells (0.5 × 10 5 -1 × 10 5 ) were placed in RPMI-1640 containing 10% FCS and IL-2 (1,000-2,000 U/ml), and were cultured for 18-24 h in plates containing the immobilized antibodies. We determined the amount of IFN-γ in the culture supernatants by using the mouse IFN-γ-specific enzyme-linked immunosorbent assay (ELISA) kit OptEIA (PharMingen) in accordance with the manufacturer's instructions.
Statistical analysis. Student's t-test was done with Excel software (Microsoft).
We used analysis of variance (Statview 5.0, SAS Institute) to compare curves. Values of P > 0.05 were considered nonsignificant and are not shown. Error bars are shown for each data point, although some are hidden by symbols.
